celastrol has been researched along with Liver Dysfunction in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Cheng, W; Ding, X; Liu, X; Wan, Y; Wu, L; Yang, B; Yang, N; Yu, S; Yu, X; Zhang, G; Zheng, J | 1 |
| Chen, LM; Guan, Y; Han, LP; Li, CJ; Ma, ZJ; Sun, B; Xie, Y | 1 |
| El-Awady, MS; El-Kashef, HA; El-Tanbouly, GS; Megahed, NA; Salem, HA | 1 |
3 other study(ies) available for celastrol and Liver Dysfunction
| Article | Year |
|---|---|
Celastrol-loaded biomimetic nanodrug ameliorates APAP-induced liver injury through modulating macrophage polarization.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents; Biomimetics; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Humans; Liver; Liver Diseases; Macrophages; Mice; Mice, Inbred C57BL; Nanoparticles | 2023 |
Protective Effects of Celastrol on Diabetic Liver Injury via TLR4/MyD88/NF-κB Signaling Pathway in Type 2 Diabetic Rats.
Topics: Animals; Anti-Inflammatory Agents; Cytoprotection; Diabetes Mellitus, Type 2; Disease Models, Animal; Interleukin-1beta; Liver; Liver Diseases; Male; Myeloid Differentiation Factor 88; NF-kappa B; Pentacyclic Triterpenes; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptor 4; Triterpenes; Tumor Necrosis Factor-alpha | 2016 |
The NF-κB inhibitor celastrol attenuates acute hepatic dysfunction induced by cecal ligation and puncture in rats.
Topics: Animals; Anti-Inflammatory Agents; Cecum; Disease Models, Animal; Gene Expression Regulation; Interleukin-10; Interleukin-6; Liver Diseases; Male; NF-kappa B; Pentacyclic Triterpenes; Rats; Toll-Like Receptor 4; Triterpenes | 2017 |